Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 28;16(13):2375.
doi: 10.3390/cancers16132375.

The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis

Jingbo Wang  1 , Ji Eun Moon  2 , Xin Guo  1 , Jiaqi Yu  1 , Junlin Yi  1 , Sun Hyun Bae  3
Affiliations
Review

The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis

Jingbo Wang et al. Cancers (Basel). .

Abstract

Background: Because of the rarity, heterogeneous histology, and diverse anatomical sites of salivary gland cancer (SGC), there are a limited number of clinical studies on its management. This study reports the cumulative evidence of postoperative radiotherapy (PORT) for SGC of the head and neck.

Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched the PubMed, Embase, Cochrane Library, and Web of Science databases between 7th and 10th November 2023.

Results: A total of 2962 patients from 26 studies between 2007 and 2023 were included in this meta-analysis. The median RT dose was 64 Gy (range: 56-66 Gy). The median proportions of high-grade, pathological tumor stage 3 or 4 and pathological lymph node involvement were 42% (0-100%), 40% (0-77%), and 31% (0-75%). The pooled locoregional control rates at 3, 5, and 10 years were 92% (95% confidence interval [CI], 89-94%), 89% (95% CI, 86-93%), and 84% (95% CI, 73-92%), respectively. The pooled disease-free survival (DFS) rates at 3, 5, and 10 years were 77% (95% CI, 70-83%), 67% (95% CI, 60-74%), and 61% (95% CI, 55-67%), respectively. The pooled overall survival rates at 3, 5, and 10 years were 84% (95% CI, 79-88%), 75% (95% CI, 72-79%), and 68% (95% CI, 62-74%), respectively. Severe late toxicity ≥ grade 3 occurred in 7% (95% CI, 3-14%).

Conclusion: PORT showed favorable long-term efficacy and safety in SGC, especially for patients with high-grade histology. Considering that DFS continued to decrease, further clinical trials exploring treatment intensification are warranted.

Keywords: postoperative radiotherapy; radiotherapy; salivary gland cancer.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest to declare.

Figures

Figure 1
Figure 1
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) algorithm.
Figure 2
Figure 2
Forest plot of (A) 3-year locoregional control (LRC), (B) 5-year LRC, (C) 3-year disease-free survival (DFS), (D) 5-year DFS, (E) 3-year DFS between cohorts treated with postoperative concurrent chemoradiotherapy (Post-op_CCRT) versus cohorts with postoperative radiotherapy alone (PORT), and (F) 3-year DFS between cohorts with the proportion of a high grade ≥ 50% versus cohorts with the proportion of a high grade < 50%.
Figure 2
Figure 2
Forest plot of (A) 3-year locoregional control (LRC), (B) 5-year LRC, (C) 3-year disease-free survival (DFS), (D) 5-year DFS, (E) 3-year DFS between cohorts treated with postoperative concurrent chemoradiotherapy (Post-op_CCRT) versus cohorts with postoperative radiotherapy alone (PORT), and (F) 3-year DFS between cohorts with the proportion of a high grade ≥ 50% versus cohorts with the proportion of a high grade < 50%.
Figure 2
Figure 2
Forest plot of (A) 3-year locoregional control (LRC), (B) 5-year LRC, (C) 3-year disease-free survival (DFS), (D) 5-year DFS, (E) 3-year DFS between cohorts treated with postoperative concurrent chemoradiotherapy (Post-op_CCRT) versus cohorts with postoperative radiotherapy alone (PORT), and (F) 3-year DFS between cohorts with the proportion of a high grade ≥ 50% versus cohorts with the proportion of a high grade < 50%.
See this image and copyright information in PMC

References

    1. Skalova A., Hyrcza M.D., Leivo I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol. 2022;16:40–53. doi: 10.1007/s12105-022-01420-1. - DOI - PMC - PubMed
    1. Young A., Okuyemi O.T. Statpearls. StatPearls Publishing; Treasure Island, FL, USA: 2023. Malignant Salivary Gland Tumors. - PubMed
    1. Dos Santos E.S., Rodrigues-Fernandes C.I., Speight P.M., Khurram S.A., Alsanie I., Normando A.G.C., Prado-Ribeiro A.C., Brandao T.B., Kowalski L.P., Guerra E.N.S., et al. Impact of Tumor Site on the Prognosis of Salivary Gland Neoplasms: A Systematic Review and Meta-Analysis. Crit. Rev. Oncol. Hematol. 2021;162:103352. doi: 10.1016/j.critrevonc.2021.103352. - DOI - PubMed
    1. Thomson D.J., Slevin N.J., Mendenhall W.M. Indications for Salivary Gland Radiotherapy. Adv. Otorhinolaryngol. 2016;78:141–147. - PubMed
    1. Spiro R.H. Management of Malignant Tumors of the Salivary Glands. Oncology. 1998;12:671–680. Discussion 683. - PubMed

LinkOut - more resources